CTCL

BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update

...prior Phase 2 study of forodesine in patients with ctcl was presented at 45th Annual Meeting of the Americ...reviewed the safety and efficacy of forodesine for ctcl patients of stage Ib to stage IV who have failed s...evelopment and commercialization of forodesine in ctcl may not be successful; that we or our licensees ma...

BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology

.... The poster entitled "Long-Term Treatment of ctcl with the Oral PNP Inhibitor, Forodesine" (Abstract...efficacy of an oral PNP inhibitor, forodesine, for ctcl patients of all stages who have failed standard th... clinical utility of forodesine as a treatment for ctcl and are encouraged by its safety and efficacy prof...

U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis System

...System and is a paid consultant for Therakos. ctcl is a type of non-Hodgkin lymphoma, a condition in ...ect the skin. "Treatment options for patients with ctcl have been limited because it is a rare disease," s...s. About Cutaneous T-cell Lymphoma (CTCL) ctcl is a type of non-Hodgkin lymphoma (NHL), a conditi...

BioCryst to Present at the 11th Annual BIO CEO & Investor Conference

...l trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009

...l trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza

...l trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008

...oint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA

...The CR duration is beyond 55 weeks with follow-up assessments ongoing. 71% of patients with evaluable SWAT scores had an improvement in skin burden of ctcl as demonstrated by a decrease in SWAT score. Enrollment is continuing into the study with a target of approximately 34 patients for each type of lymph...

BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007

...ed, it may not be successful, that the pivotal trial with forodesine HCl in ctcl may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasi... that development and commercialization of forodesine HCl in both T-ALL and ctcl may not be successful, that we may not resolve satisfactorily the particula...

Allos Therapeutics Reports Third Quarter 2007 Financial Results

...to report the outcome of the 65-patient safety analysis by the end of 2007 and complete enrollment in the trial in the second quarter of 2008. PDX in ctcl In August 2007, the Company announced the initiation of patient enrollment in a Phase 1, open-label, multi-center study of PDX with vitamin B12 and f...

CTCL in Medical Technology

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

... pivotal trial with forodesine in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint; that development and commercialization of forodesine in ctcl may not be successful; that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections

...l trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio

... zanolimumab pivotal study has been slow which the company believes is due to the relatively small market potential in CTCL, the introduction of a new ctcl therapeutic to the market and numerous competing clinical trials. In the light of these issues, Genmab considers that the significant investment requi...

BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting

...oint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza

...oint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)

...olled Phase III Trial; Largest Enrollment of ctcl Patients in a Randomized Study WOODCLIFF LAKE, N...treatment of patients with persistent or recurrent ctcl whose malignant cells express the CD25 component o... The safety and efficacy of ONTAK in patients with ctcl whose malignant cells do not express the CD25 comp...

BioCryst Updates Peramivir Clinical Development Plan

...rogram may not be successful, that the pivotal trial with forodesine HCl in ctcl may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasi...ully completed, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll t...

Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma

...ed, it may not be successful, that the pivotal trial with forodesine HCl in ctcl may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasi...ully completed, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll t...

BioCryst Provides Forodesine HCl Update

...r clinical trials of forodesine HCl, including the ctcl trials, which are utilizing the oral capsule formu...oCryst. "We believe that by retaining our focus on ctcl we will be able to bring forodesine HCl to market ...lier this year. Eligible patients are those with ctcl of Stages IB through IVA who have disease that is ...

BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)

...provide data to establish forodesine HCL as a new treatment alternative for ctcl patients who have not responded to currently available therapies." "Initia...erein include that our belief that the pivotal trial with forodesine HCL in ctcl may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasi...

CTCL in Biological News

Source of molecular triggers in cutaneous T cell lymphoma identified

...nto large populations of malignant lymphocytes. ctcl is the most common adult malignancy of T lymphocyt...he white blood cells of the immune system. Finding ctcl triggering factors has been a major goal of Richar... at the National Cancer Institute first identified ctcl as a separate category of lymphoma thirty years ag...

CTCL in Biological Technology

Genmab Amends HuMax-CD4 Pivotal Study in CTCL

Receives Orphan Drug Designation for Nodal T-Cell Lymphoma Summary: Genmab Announced Today it has Amended the Ongoing HuMax-CD4 Pivotal Study to Treat Refractory CTCL and has Received an Orphan Drug Designation for the Treatment of Nodal T-Cell Lymphoma COPENHAGEN, Denmark, ...

Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma

...ymphoma. Over one percent (1%) of all people with ctcl in the United States have enrolled in the study. ...e are approximately 16,000 to 20,000 patients with ctcl in the United States and each year approximately 2...therapy available for the treatment of early-stage ctcl in almost a decade. "Cutaneous T-cell lymphom...

BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update

...l trial with Forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of Forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference

...l trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition

...l trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update

...in San Francisco, December 6-9, 2008. -- The forodesine HCl pivotal trial in cutaneous T-cell lymphoma (CTCL) continues to enroll subjects with ctcl stages IIB through IVA who have failed three systemic therapies. The multinational study is evaluating once daily oral forodesine HCL treat...

BioCryst to Present at the JMP Healthcare Focus Conference

...oint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

BioCryst to Present at UBS 2008 Global Life Sciences Conference

...oint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...

Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL

...rapy in patients with recurrent or refractory cutaneous (CTCL) or peripheral T-cell lymphoma (PTCL). Efficacy is being analyzed separately in PTCL and ctcl patients. In 11 patients evaluable for response in the PTCL arm, 2 durable complete responses (CR) and 4 Stable Diseases (SD) have been observed as an...

BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008

...oint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in ctcl may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product ca...